Back to Search
Start Over
Clinical and pharmacokinetic characteristics of intracavitary administration of pegylated liposomal encapsulated doxorubicin in dogs with splenic hemangiosarcoma.
- Source :
-
Journal of veterinary internal medicine [J Vet Intern Med] 2007 Nov-Dec; Vol. 21 (6), pp. 1347-54. - Publication Year :
- 2007
-
Abstract
- Background: Canine splenic hemangiosarcoma (HSA) is a fatal malignancy, and most affected dogs die within a few months of diagnosis. Most dogs present with signs from tumor rupture, resulting in hemoabdomen and intra-abdominal dissemination. The abdomen is also the main site of disease recurrence.<br />Hypothesis: Intraperitoneal (IP) administration of doxorubicin will delay or prevent intra-abdominal tumor recurrence and prolong survival in dogs with HSA.<br />Animals: Fourteen dogs with splenic HSA.<br />Methods: A prospective, unmasked, uncontrolled clinical trial. After staging of disease status and splenectomy, pegylated liposomal encapsulated doxorubicin was administered intraperitoneally (1 mg/kg body weight) every 3 weeks for 4 cycles. All dogs were monitored for recurrence of HSA. Samples of plasma and abdominal fluid were collected for measurement of doxorubicin concentration and pharmacokinetic analysis. Nonlinear mixed-effect modeling was used to describe the pharmacokinetics of liposomal doxorubicin administered IP.<br />Results: All 14 dogs died, 12 because of HSA and 2 from other causes. Postmortem examination was performed on 12 dogs. All 12 dogs died because of HSA-related causes and had hepatic metastases and hemoabdomen. The IP-treated dogs had fewer serosal, mesenteric, and omental metastases than historical controls treated with systemic doxorubicin. Results of the postmortem examination and pharmacokinetic analysis confirmed that IP delivery of doxorubicin resulted in an effective drug concentration with a clearance comparable with that after i.v. delivery.<br />Conclusions and Clinical Importance: IP pegylated liposomal encapsulated doxorubicin administration did not prevent intraabdominal recurrence of HSA in dogs.
- Subjects :
- Animals
Dogs
Doxorubicin pharmacokinetics
Doxorubicin therapeutic use
Hemangiosarcoma drug therapy
Splenic Neoplasms drug therapy
Antineoplastic Agents pharmacokinetics
Antineoplastic Agents therapeutic use
Dog Diseases drug therapy
Doxorubicin analogs & derivatives
Hemangiosarcoma veterinary
Polyethylene Glycols pharmacokinetics
Polyethylene Glycols therapeutic use
Splenic Neoplasms veterinary
Subjects
Details
- Language :
- English
- ISSN :
- 0891-6640
- Volume :
- 21
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Journal of veterinary internal medicine
- Publication Type :
- Academic Journal
- Accession number :
- 18196746
- Full Text :
- https://doi.org/10.1892/06-214.1